GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (NAS:OPGN) » Definitions » Beneish M-Score

OpGen (OPGN) Beneish M-Score : -5.49 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OpGen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -5.49 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for OpGen's Beneish M-Score or its related term are showing as below:

OPGN' s Beneish M-Score Range Over the Past 10 Years
Min: -6.1   Med: -2.74   Max: 18.73
Current: -5.49

During the past 10 years, the highest Beneish M-Score of OpGen was 18.73. The lowest was -6.10. And the median was -2.74.


OpGen Beneish M-Score Historical Data

The historical data trend for OpGen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Beneish M-Score Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.33 3.13 0.48 -2.66 -5.34

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.39 -5.34 -2.65 -4.83 -5.49

Competitive Comparison of OpGen's Beneish M-Score

For the Medical Devices subindustry, OpGen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where OpGen's Beneish M-Score falls into.



OpGen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of OpGen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6862+0.528 * -1.9765+0.404 * 1.081+0.892 * 0.9269+0.115 * 1.5094
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0048+4.679 * -0.217645-0.327 * 1.483
=-5.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $0.42 Mil.
Revenue was 0.699 + 0.736 + 0.913 + 0.722 = $3.07 Mil.
Gross Profit was 0.007 + -0.182 + 0.193 + 0.186 = $0.20 Mil.
Total Current Assets was $3.46 Mil.
Total Assets was $18.14 Mil.
Property, Plant and Equipment(Net PPE) was $5.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.41 Mil.
Selling, General, & Admin. Expense(SGA) was $12.60 Mil.
Total Current Liabilities was $12.47 Mil.
Long-Term Debt & Capital Lease Obligation was $2.83 Mil.
Net Income was -4.063 + -5.827 + -5.737 + -10.535 = $-26.16 Mil.
Non Operating Income was -0.126 + -0.018 + -0.079 + -5.353 = $-5.58 Mil.
Cash Flow from Operations was -2.928 + -4.753 + -4.963 + -3.995 = $-16.64 Mil.
Total Receivables was $0.67 Mil.
Revenue was 0.449 + 0.967 + 0.47 + 1.426 = $3.31 Mil.
Gross Profit was -1.455 + 0.305 + 0.147 + 0.568 = $-0.44 Mil.
Total Current Assets was $13.39 Mil.
Total Assets was $32.96 Mil.
Property, Plant and Equipment(Net PPE) was $4.53 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.91 Mil.
Selling, General, & Admin. Expense(SGA) was $13.53 Mil.
Total Current Liabilities was $12.01 Mil.
Long-Term Debt & Capital Lease Obligation was $6.74 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.423 / 3.07) / (0.665 / 3.312)
=0.137785 / 0.200785
=0.6862

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-0.435 / 3.312) / (0.204 / 3.07)
=-0.131341 / 0.06645
=-1.9765

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.455 + 5.737) / 18.135) / (1 - (13.392 + 4.532) / 32.959)
=0.493135 / 0.456173
=1.081

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3.07 / 3.312
=0.9269

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.914 / (1.914 + 4.532)) / (1.405 / (1.405 + 5.737))
=0.296928 / 0.196724
=1.5094

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(12.603 / 3.07) / (13.532 / 3.312)
=4.105212 / 4.085749
=1.0048

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.83 + 12.472) / 18.135) / ((6.741 + 12.012) / 32.959)
=0.843783 / 0.56898
=1.483

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-26.162 - -5.576 - -16.639) / 18.135
=-0.217645

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

OpGen has a M-score of -5.49 suggests that the company is unlikely to be a manipulator.


OpGen (OPGN) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Executives
Yvonne Schlaeppi director 600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893
Johannes Bacher officer: Chief Operating Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Albert Weber officer: Chief Finanical Officer MARIENBURGER STR. 7, BERLIN 2M 10405
Oliver Schacht director, officer: Chief Executive Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Evan/ Fa Jones director, officer: Chief Executive Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
William E. Rhodes director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Curetis N.v. In Liquidation 10 percent owner MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088
Mario Crovetto director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Vadim M. Sapiro officer: Chief Information Officer C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Timothy C Dec officer: Chief Financial Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Jven Capital, Llc 10 percent owner P.O. BOX 60207, POTOMAC MD 20859
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Harry J D'andrea director 6480 DOBBIN ROAD, COLUMBIA MD 21045